Researchers at Ruhr University Bochum have developed a novel antiviral concept: using the CRISPR/Cas13 system, they were able to specifically suppress the replication of hepatitis E virus in human cells. Hepatitis E is a common cause of acute liver inflammation worldwide, yet effective specific treatments are still lacking. The team has now demonstrated that the virus can be targeted using the RNA-guided CRISPR system. The results, published May 4, 2026, in the journal JHEP Reports, open new perspectives for the development of antiviral strategies.
Please follow and like us:
